Clinical Trials Logo

T2DM clinical trials

View clinical trials related to T2DM.

Filter by:

NCT ID: NCT05996380 Recruiting - T2DM Clinical Trials

A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes

Start date: June 9, 2023
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, single-dose escalation trial was designed. There are 6 dose groups and 1 optional dose group: 0.5 mg, 2 mg, 8 mg, 25mg, 50 mg, 100 mg and 150 mg (optional). Eight healthy adult subjects or T2DM patients in each dose group (except for 0.5 mg dose group, only 4 subjects will be enrolled) are randomly assigned to subcutaneously injection of SHR-3167 or placebo according to 3:1 ratio.

NCT ID: NCT05681273 Completed - T2DM Clinical Trials

Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.

Start date: February 17, 2023
Phase: Phase 1
Study type: Interventional

This Phase 1 open label study is being conducted to characterize the pharmacokinetic (PK) and safety profiles of Chiglitazar with Empagliflozin,Atorvastatin and Valsartan in healthy subjects.

NCT ID: NCT05680155 Active, not recruiting - Clinical trials for Type 2 Diabetes Mellitus

A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients

Start date: December 29, 2022
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to investigate the efficacy and safety of XW003 versus placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled by diet and exercise alone

NCT ID: NCT05680129 Active, not recruiting - Clinical trials for Type 2 Diabetes Mellitus

A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM

Start date: January 10, 2023
Phase: Phase 3
Study type: Interventional

The aim of the study is to compare the efficacy and safety of two XW003 doses versus dulaglutide as add-on therapy to metformin in participants with type 2 diabetes mellitus (T2DM)

NCT ID: NCT05159882 Recruiting - T2DM Clinical Trials

Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM

Start date: April 15, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the effect of THR-1442 compared to Dapagliflozin as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).

NCT ID: NCT04609631 Active, not recruiting - Depression Clinical Trials

Tai Chi for Comorbid Depression in T2DM Patients

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Previous studies suggested that Tai Chi may be beneficial for T2DM patients. However, no studies have investigated the effectiveness of Tai Chi for comorbid depression in T2DM patients, as well as the optimal frequency of Tai Chi. Thus, we intend to investigate the effectiveness of Tai Chi for comorbid depression in T2DM patients and test whether the effectiveness of Tai Chi depends on its frequency.

NCT ID: NCT04544319 Not yet recruiting - T2DM Clinical Trials

Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg

Start date: October 2020
Phase: Phase 1
Study type: Interventional

To identify bioequivalence between Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg to Each Component of Gemigliptin 50 mg and Dapagliflozin 10 mg

NCT ID: NCT03564431 Recruiting - T2DM Clinical Trials

The Imaging Genetic Study of Type 2 Diabetes and Depression

Start date: December 1, 2017
Phase:
Study type: Observational

To investigate the structural/functional abnormalities and the possible genetic endophenotypes of in the Type 2 Diabetes Patient With Depression.

NCT ID: NCT03563794 Recruiting - T2DM Clinical Trials

Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes

Start date: June 10, 2018
Phase: Phase 4
Study type: Interventional

The randomized, controlled clinical trial investigate the efficacy and safety of vildagliptin added to continuous subcutaneous insulin infusion in uncontrolled type 2 diabetes

NCT ID: NCT02037100 Recruiting - Obesity Clinical Trials

Sleep Disordered Breathing and Impaired Glucose Homeostasis in Obese Children

Start date: June 2007
Phase: N/A
Study type: Observational

SDB has been identified as an important risk factor for insulin resistance and the metabolic syndrome. In a recent study in patients with SDB and T2DM it was shown that CPAP therapy can lead to improvements in postprandial glucose levels and in glycosylated hemoglobin levels (HbA1c). In children, there are only 3 studies that have examined the relations between SDB, obesity and the metabolic syndrome. In order to further understand the relative contribution of SDB to the development of impaired glucose homeostasis and metabolic abnormalities we aim to investigate the prevalence and severity of SDB in children with T2DM compared to obese children without T2DM. The investigators hypothesize that SDB will be more prevalent and more severe among obese children with T2DM compared with the general obese pediatric population.